Clinical Trial

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Study acronym: OCTAGON
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-10
Trial Details
NCT Number NCT07221838
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Generalized Myasthenia Gravis, gMG
Enrollment 75 participants
Start Date 2026-03-04
Primary Completion 2027-08-27 (estimated)
Study Completion 2027-08-27 (estimated)
Updated on ClinicalTrials.gov 2026-04-09